Agenda

Boardroom panel: Creating a robust ecosystem for pharma in India

India is poised to become a top 5 global pharmaceutical hub by 2020. But in order to achieve this, there’s work to be done, to develop a successful ecosystem. Key stakeholders including the government, pharma, regulators and investors need to work closely together to build it. In this panel, we gather them to explore how, as we explore issues including:
 

• How will the creation of new pharma clusters across India help enhance the ecosystem?
• How is the Indian government playing an active role to help build up the ecosystem? (Building infrastructure, funding of incubators and accelerators, mission mode programmes)
• Should a robust and sustainable ecosystem be centred around academic institutes to increase collaboration?
• What are some existing models which India can emulate? (Boston,SF Bay area, Singapore, BioValley)
• Is achieving that too idealistic? How far is India from achieving that?

Sustainability of Vaccines Industry: Coping with pricing pressures

India is supplying more than 60% of the vaccines procured by GAVI. Vaccines in the public market are older and mass manufactured. Due to the cost of production, new vaccines are not able to enter the market. Should local vaccine manufacturers focus on ensuring cheap production of old vaccines for the public market or should they develop new vaccines for their private market instead? This session will explore differences between public & private markets, together with strategies for navigating the public market.

• Comparing the differences between public and private market in terms of development and production cost
• Understanding the differences in demands for both markets
• What are some challenges that are unique to the public market? (E.g. Price pressures from GAVI, WHO)
• Explore strategies in overcoming these challenges to achieve a sustainable model